Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Atkins

Showing results (291-300 of 493) with videos related to

Pageof 50
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1992
A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinomaG R Weiss, K A Margolin, F R Aronson, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|October 1, 1994
Phase II trials of high-dose interleukin-2 and lymphokine-activated killer cells in advanced breast carcinoma and carcinoma of the lung, ovary, and pancreas and other tumorsJ A Sparano, R I Fisher, G R Weiss, et al.
Translational Oncology|April 8, 2014
The role of angiopoietins as potential therapeutic targets in renal cell carcinomaXiaoen Wang, Andrea J Bullock, Liang Zhang, et al.
Blood|October 25, 2001
Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosisA Kaser, G Brandacher, W Steurer, et al.
Journal for Immunotherapy of Cancer|March 6, 2019
Exceptional response and multisystem autoimmune-like toxicities associated with the same T cell clone in a patient with uveal melanoma treated with immune checkpoint inhibitorsSuthee Rapisuwon, Benjamin Izar, Cory Batenchuk, et al.
Journal of Cancer Research and Clinical Oncology|April 6, 2002
Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working GroupK Margolin, B Atkins, A Thompson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1994
Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanomaM B Atkins, K R O'Boyle, J A Sosman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2009
Phase II multicenter trial of maintenance biotherapy after induction concurrent Biochemotherapy for patients with metastatic melanomaSteven J O'Day, Michael B Atkins, Peter Boasberg, et al.
Cancer|October 19, 2006
Treatment of patients with metastatic renal cell cancer: a RAND Appropriateness PanelRonald J Halbert, Robert A Figlin, Michael B Atkins, et al.
Radiology|May 29, 2009
Does arterial spin-labeling MR imaging-measured tumor perfusion correlate with renal cell cancer response to antiangiogenic therapy in a mouse model?Rachel Schor-Bardach, David C Alsop, Ivan Pedrosa, et al.
Pageof 50

Showing results (291-300 of 493) with videos related to

Sort By:
Pageof 50
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1992
A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinomaG R Weiss, K A Margolin, F R Aronson, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|October 1, 1994
Phase II trials of high-dose interleukin-2 and lymphokine-activated killer cells in advanced breast carcinoma and carcinoma of the lung, ovary, and pancreas and other tumorsJ A Sparano, R I Fisher, G R Weiss, et al.
Translational Oncology|April 8, 2014
The role of angiopoietins as potential therapeutic targets in renal cell carcinomaXiaoen Wang, Andrea J Bullock, Liang Zhang, et al.
Blood|October 25, 2001
Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosisA Kaser, G Brandacher, W Steurer, et al.
Journal for Immunotherapy of Cancer|March 6, 2019
Exceptional response and multisystem autoimmune-like toxicities associated with the same T cell clone in a patient with uveal melanoma treated with immune checkpoint inhibitorsSuthee Rapisuwon, Benjamin Izar, Cory Batenchuk, et al.
Journal of Cancer Research and Clinical Oncology|April 6, 2002
Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working GroupK Margolin, B Atkins, A Thompson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1994
Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanomaM B Atkins, K R O'Boyle, J A Sosman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2009
Phase II multicenter trial of maintenance biotherapy after induction concurrent Biochemotherapy for patients with metastatic melanomaSteven J O'Day, Michael B Atkins, Peter Boasberg, et al.
Cancer|October 19, 2006
Treatment of patients with metastatic renal cell cancer: a RAND Appropriateness PanelRonald J Halbert, Robert A Figlin, Michael B Atkins, et al.
Radiology|May 29, 2009
Does arterial spin-labeling MR imaging-measured tumor perfusion correlate with renal cell cancer response to antiangiogenic therapy in a mouse model?Rachel Schor-Bardach, David C Alsop, Ivan Pedrosa, et al.
Pageof 50